Neuroscience

Almost 10 million people worldwide are living with Parkinson’s disease, leaving those affected with muscular rigidity, tremors and cognitive decline. Innovative research aims to investigate ways to improve the standard of care and quality of life.

It’s more than just a headache. Impacting 1 billion people around the world, migraine is a neurological disease that causes pain and debilitating symptoms. Our science is helping healthcare providers to care for people across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help patients and their families navigate barriers to care, access effective treatments and reduce the impact of migraine on their lives.

Movement disorders are chronic and progressive neurological conditions impacting the body’s ability to control movement. Our commitment to people living with movement disorders is unwavering, evidenced by decades of history in this area of research. Our scientists are developing treatments that mitigate symptoms, with other efforts focused on raising awareness for the importance of prompt diagnosis and management.

Millions of people worldwide are affected by psychiatric disorders, which remain prevalent now, more than ever. Over the last 30 years, AbbVie scientists and clinicians have worked to tackle the complexity of mental illness and today offer a portfolio of medicines and a pipeline that spans depression, anxiety, bipolar disorder and schizophrenia.

According to the Alzheimer’s Association, the number of older adults with Alzheimer’s type dementia will have increased over threefold by 2050. Alzheimer’s disease is marked by changes in memory, language and the ability to carry out tasks like cooking or driving. Our work at AbbVie not only includes diving into potentially groundbreaking Alzheimer’s research but also exploring the scientific complexities of aging as a whole.